23Strands
- Company typePrivate
- Founded2019
- HeadquartersPyrmont, Australia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
23Strands firmographics
Firmographics- Name
- 23Strands
- Legal name
- 23Strands
- Website
- https://23strands.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
23Strands industry classification
Industry- Product category
- Clinical Genomics / Precision Medicine
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE) (HLACABAA), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Public Health Genomics & Sequencing (WGS/Metagenomics) Networks (HLAJAIAK)
Keywords
Where 23Strands is headquartered
LocationHeadquarters
- HQ city
- Pyrmont
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
23Strands business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Genomic Testing Services: Whole genome sequencing and AI-powered genomic analysis services for patients and clinicians. The company analyses entire genomes to provide personalised health insights across fertility, cardiovascular disease, and other conditions. Services are delivered through clinical partnerships and direct patient engagement.
- Geneve Health Platform Services: Commercial precision medicine services for women's and reproductive health delivered through the wholly-owned subsidiary Geneve Health, encompassing genetic assessments with family planning specialists, ongoing care management through virtual clinics, and customisable benefit packages for payers and employers.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
23Strands product offering
Product offeringCore offering
23Strands provides whole genome sequencing (WGS) combined with proprietary AI and deep neural network analytics to deliver personalised, precision-medicine health insights for patients and clinicians. Its portfolio spans a core genomic platform and specialty programs including Fertility23 (unexplained infertility DNA analysis), Cardio23 (polygenic cardiovascular risk prediction), 23Plus (patient-facing WGS), the Biblioengine research tool, and Geneve Health — a wholly-owned subsidiary launched January 2026 focused on women's and reproductive health precision medicine delivered via a secure patient portal with EHR integration.
Product overview
23Strands is a genomics healthcare technology company offering a core platform (23Strands Platform) for whole genome sequencing analysis combined with AI. The product portfolio includes specialty verticals: Fertility23 for fertility/infertility genetic analysis, Cardio23 for cardiovascular disease prediction, and Geneve Health (a wholly-owned subsidiary launched January 2026) for women's and reproductive precision medicine. Supporting products include 23Plus (patient-facing WGS) and the Biblioengine research tool. The platform integrates genomic data with clinical records and provides AI-powered analytics, connecting patients with multidisciplinary care pathways.
Differentiator
Problem solved
Functional benefit
Brands
- Geneve: Comprehensive women's and reproductive health program built on cutting-edge precision medicine, including personalised genetic insights, AI-powered clinical decision support, and whole-of-life care continuum from preconception through elderly care.
Products and services
- 23Strands Platform Core genomic analysis platform that combines whole genome sequencing with AI to deliver comprehensive personalised health insights, integrated with clinical records and connected to multidisciplinary care pathways for patients and clinicians.
- Fertility23 Specialty fertility product using DNA analysis to identify potential causes of unexplained infertility; provides precision analysis and recommendations for both patients and clinicians, analysing individual genetic variations that affect fertility outcomes.
- Geneve Health Wholly-owned subsidiary delivering advanced genomic analytics tailored for fertility, pregnancy outcomes, and hormonal health, with AI-powered clinical decision support and a whole-of-life care continuum spanning preconception to elderly care through a secure patient portal with family-sharing.
Quantifiable outcome
- Improved cardiovascular disease prediction accuracy by 21% compared to previous methods using deep neural networks analysing both indel variants and SNVs from whole genome sequences
- +3 more outcomes
Companies that use 23Strands
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
23Strands technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature7 records
23Strands partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major, minor and supporting.
- Geneve Health Pty LtdcoreGeneve Health Pty Ltd is a wholly 23Strands owned and dedicated entity, exclusively focused on advancing precision medicine in women's and reproductive health. Launched commercially in January 2026, Geneve delivers advanced genomic analytics tailored for fertility, pregnancy outcomes, and hormonal health, AI-powered clinical decision support, and a whole-of-life care continuum spanning preconception to elderly care.
- Monash Universitycore23Strands partnered with Monash University (led by Professor Beverley Vollenhoven) and Virtus Health for a world-first AI IVF study. The collaboration integrates genomics, artificial intelligence, and clinical care to set a new global standard for personalised IVF medication dosing. The MRFF grant of $3 million funds the four-year research program.
- Virtus HealthcoreVirtus Health, a major IVF service provider and the first to develop AI embryo selection software, partnered with 23Strands for a world-first AI IVF study. The partnership aims to offer whole-genome sequencing and AI to augment reproductive decision-making and help patients achieve their dream of starting a family. Virtus Health CEO James Pyne endorsed the project.
- TRIASmajor23Strands and TRIAS signed a memorandum of understanding (MOU) to advance genomics in healthcare. The collaboration aims to: identify methods for medical diagnosis and treatment using genomics and clinical reports; identify standards, ethics, and governance for clinical genomic translation; develop a data pipeline for clinical genomic services including whole human genomics, variant calling, and outcome data analysis; identify and co-develop new research projects; collaborate on co-marketing efforts; plan team and training development; and explore international market opportunities.
- University of Technology Sydney (UTS) / Australian Artificial Intelligence Institutecore23Strands partnered with the UTS Australian Artificial Intelligence Institute (led by Professor Jie Lu) for a highly competitive Australian Research Council (ARC Linkage) Grant on applying AI in analysis, management, and clinical recommendation for personalised disease treatment. The project is split into three main areas: AI analysis of Whole Human Genome Sequencing data, intelligent computer-aided recommendations integrating medical records with genomics, and healthcare pathway optimisation. Total project funding exceeds $2.2 million over 3 years.
- Victor Chang Cardiac Research Instituteminor23Strands conducted a joint research project with the Victor Chang Cardiac Research Institute (along with UTS and Sydney Heart Bank) to unveil genomic differences between peripartum cardiomyopathy (PPCM) and other forms of cardiomyopathy. The research used the Biblioengine prototype and AI to identify genes associated with PPCM.
- Sydney Heart Bankminor23Strands collaborated with the Sydney Heart Bank (along with UTS and Victor Chang Cardiac Research Institute) on a joint research project identifying genomic distinctions between peripartum cardiomyopathy and other forms of cardiomyopathy.
- Haventecsupporting23Strands partnered with Australian cybersecurity company Haventec on the eConsent for Genomics platform, supported by AustCyber. This decentralised platform enables confidential genomic testing consent and secure data storage. 23Strands plans to roll out this solution in the community for greater protection of sensitive genomic information.
- OraclesupportingOracle is described as a commercial healthcare informatics partner of 23Strands. The partnership is noted in the context of Oracle's acquisition of Cerner (a major EHR vendor) for $28 billion. 23Strands expressed excitement about future opportunities and innovations this acquisition would bring to Oracle and the 23Strands team.
- Australian National University (ANU) / Professor Alex Brownmajor23Strands received Medical Research Future Funding to play an integral and leading role in researching the benefit of genomic medicine to Indigenous Australians. Professor Alex Brown from ANU leads a five-year collaboration to establish the National Indigenous Genomics Network, engaging Indigenous Australians in genetic research and healthcare in a culturally safe way.
- Industry Genomic Network Alliance (InGeNA)supporting23Strands is a founding member of InGeNA, contributing to the development of the industry review 'Genomic Data in Australia,' which highlights the importance of data management in health and genomics and supports advancement within Australia's healthcare landscape.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
23Strands competitors and assessment
Company assessmentDirect peers
- Personalis: US clinical genomics company focused on whole genome sequencing-based tests for cancer and other diseases, with proprietary analytics pipelines. Comparable to 23Strands' deep WGS + AI interpretation stack.
- Color Genomics: US clinical genetics company offering WGS- and panel-based testing across hereditary cancer, cardiovascular, and reproductive health, with employer/payer distribution. Overlaps directly with 23Strands' Fertility23 and Cardio23 verticals and its Geneve Health payer/employer model.
- Genomics plc: UK-based company that uses large-scale genomic and phenotypic data to build polygenic risk prediction models for common diseases. Directly comparable to 23Strands' deep-neural-network approach to cardiovascular polygenic prediction.
- Gene by Gene: US clinical and consumer genomics laboratory offering whole genome and whole exome sequencing with clinical interpretation services. Directly comparable to 23Strands as a CLIA-style clinical WGS provider.
- Helix: US-based clinical genomics company built around a whole genome sequencing platform with clinical-grade bioinformatics, partner integrations, and population health programs. Directly comparable to 23Strands in using WGS (rather than targeted panels) as the foundation for clinical insights.
Broad incumbents
- Myriad Genetics: Established US clinical genetics company spanning hereditary cancer, women's health, and pharmacogenomics with deep reimbursement infrastructure. A broad incumbent in the precision-medicine category where 23Strands is competing with focused specialty verticals.
- Sema4 (now GeneDx): US-based clinical genomics and data platform offering hereditary disease, reproductive health, and oncology testing paired with AI-driven interpretation. Comparable as a broader incumbent offering clinical genomic interpretation at scale across similar use cases to 23Strands.
- 23andMe: Consumer and clinical genomics company with large-scale genomic database, polygenic risk scores, and pharma collaborations. Comparable to 23Strands as a major player in consumer/clinical genomics and polygenic disease prediction, though at vastly greater scale.
Regional players
- Genetic Technologies (GTG): Australian-listed clinical genomics company offering hereditary cancer risk and polygenic risk tests across the Australian and Asian markets. Regional peer competing in the same domestic market as 23Strands with overlapping genomic risk prediction offerings.
Emerging players
- BC Platforms: Switzerland-based genomic data and analytics platform offering clinical interpretation, biobanking, and translational informatics. Comparable to 23Strands on the bioinformatics/clinical interpretation and data-pipeline layer, including their TRIAS MOU partner-type activities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
23Strands social profiles
Digital presence23Strands financial estimates
Financial estimateRevenue estimate
Valuation estimate
23Strands leadership team
Management profileNumber of profiles
Profiles3 records
23Strands subsidiaries and ownership
Company hierarchySubsidiaries1 record
23Strands funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
23Strands M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 23Strands
What does 23Strands do?
23Strands provides whole genome sequencing (WGS) combined with proprietary AI and deep neural network analytics to deliver personalised, precision-medicine health insights for patients and clinicians. Its portfolio spans a core genomic platform and specialty programs including Fertility23 (unexplained infertility DNA analysis), Cardio23 (polygenic cardiovascular risk prediction), 23Plus (patient-facing WGS), the Biblioengine research tool, and Geneve Health — a wholly-owned subsidiary launched January 2026 focused on women's and reproductive health precision medicine delivered via a secure patient portal with EHR integration.
Is 23Strands a public or private company?
23Strands is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 23Strands founded?
23Strands was founded in 2019. It employs 11 to 50 people.
Where is 23Strands based?
23Strands is headquartered in Pyrmont, Australia, in the Oceania region.
How does 23Strands make money?
Two revenue lines are on record. Genomic Testing Services are the primary driver. The others are geneve Health Platform Services.
Who are 23Strands's main competitors?
Direct peers on record are Personalis, Color Genomics, Genomics plc, Gene by Gene and Helix. Broad incumbents are Myriad Genetics, Sema4 (now GeneDx) and 23andMe. Genetic Technologies (GTG) is listed as a regional player. BC Platforms is listed as an emerging player.
Does 23Strands have an API?
No public API is recorded for 23Strands.
What industry is 23Strands in?
23Strands's product category is Clinical Genomics / Precision Medicine. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 62151 and its SIC code is 2835.